Activity of daptomycin against staphylococci collected from bloodstream infections in Spanish medical centers

Diagnostic Microbiology and Infectious Disease

Volumn 64, Issue 4, 2009, Pages 448-451

  Picazo, Juan J ^a   Betriu, Carmen ^a   Culebras, Esther ^a   Rodríguez Avial, Iciar ^a   Gómez, María ^a   López, Fátima ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

Bloodstream infections; Daptomycin; Staphylococci

Indexed keywords

CHLORAMPHENICOL; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; ERYTHROMYCIN; GENTAMICIN; LINEZOLID; OXACILLIN; RIFAMPICIN; TEICOPLANIN; TETRACYCLINE; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BLOODSTREAM INFECTION; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONTROLLED STUDY; HUMAN; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; SPAIN; STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; BACTEREMIA; DAPTOMYCIN; HOSPITALS; HUMANS; METHICILLIN RESISTANCE; MICROBIAL SENSITIVITY TESTS; SPAIN; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS;

EID: 67650751331     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2009.03.020     Document Type: Article

References (22)

1. Castanheira M., Jones R.N., and Sader H.S. Update of the in vitro activity of daptomycin tested against 6710 Gram-positive cocci isolated in North America (2006). Diagn. Microbiol. Infect. Dis. 61 (2008) 235-239
2. Chua T., Moore C.L., Perri M.B., Donabedian S.M., Masch W., Vager D., Davis S.L., Lulek K., Zimnicki B., and Zervos M.J. Molecular epidemiology of methicillin-resistant Staphylococcus aureus bloodstream isolates in urban Detroit. J. Clin. Microbiol. 46 (2008) 2345-2352
3. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically; approved standard-seventh edition, M7-A7 (2006), CLSI, Wayne, PA
4. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing, 18th informational supplement, M100-S18 (2008), CLSI, Wayne, PA
5. Cuevas O., Cercenado E., Goyanes M.J., Vindel A., Trincado P., Boquete T., Marin M., and Bouza E. Staphylococcus spp. en España: situación actual y evolución de la resistencia a antimicrobianos (1986-2006). Enferm. Infecc. Microbiol. Clin. 26 (2008) 269-277
6. De la Torre M., Sánchez M., Morales G., Baos E., Arribi A., García N., Andrade R., Peláez B., Pacheco M.P., Domingo S., Conesa J., Nieto M., Candel F.J., and Picazo J.J. Outbreak of linezolid-resistant Staphylococcus aureus in intensive care. Abstracts of the 48th Intersc. Conf. Antimicrob. Agents Chemother (2008) 322 abstract C2--1835a
7. Fowler Jr. V.G., Miro J.M., Hoen B., Cabell C.H., Abrutyn E., Rubinstein E., Corey G.R., Spelman D., Bradley S.F., Barsic B., Pappas P.A., Anstrom K.J., Wray D., Fortes C.Q., Anguera I., Athan E., Jones P., van der Meer J.T., Elliott T.S., Levine D.P., and Bayer A.S. Staphylococcus aureus endocarditis: a consequence of medical progress. JAMA 293 (2005) 3012-3021
8. Fowler Jr. V.G., Boucher H.W., Corey G.R., Abrutyn E., Karchmer A.W., Rupp M.E., Levine D.P., Chambers H.F., Tally F.P., Vigliani G.A., Cabell C.H., Link A.S., DeMeyer I., Filler S.G., Zervos M., Cook P., Parsonnet J., Bernstein J.M., Price C.S., Forrest G.N., Fatkenheuer G., Gareca M., Rehm S.J., Brodt H.R., Tice A., and Cosgrove S.E. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N. Engl. J. Med. 355 (2006) 653-665
9. Gales A.C., Sader H.S., Andrade S.S., Lutz L., Machado A., and Barth A.L. Emergence of linezolid-resistant Staphylococcus aureus during treatment of pulmonary infection in a patient with cystic fibrosis. Int. J. Antimicrob. Agents 27 (2006) 300-302
10. Garnier F., Chainier D., Walsh T., Karlsson A., Bolmstrom A., Grelaud C., Mounier M., Denis F., and Ploy M.C. A 1 year surveillance study of glycopeptide-intermediate Staphylococcus aureus strains in a French hospital. J. Antimicrob. Chemother. 57 (2006) 146-149
11. Lodise T.P., Graves J., Evans A., Graffunder E., Helmecke M., Lomaestro B.M., and Stellrecht K. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob. Agents. Chemother. 52 (2008) 3315-3320
12. Luh K.T., Hsueh P.R., Teng L.J., Pan H.J., Chen Y.C., Lu J.J., Wu J.J., and Ho S.W. Quinupristin-dalfopristin resistance among gram-positive bacteria in Taiwan. Antimicrob. Agents Chemother. 44 (2000) 3374-3380
13. Moise-Broder P.A., Sakoulas G., Eliopoulos G.M., Schentag J.J., Forrest A., and Moellering Jr. R.C. Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy. Clin. Infect. Dis. 38 (2004) 1700-1705
14. Pfaller M.A., Sader H.S., and Jones R.N. Evaluation of the in vitro activity of daptomycin against 19615 clinical isolates of Gram-positive cocci collected in North American hospitals (2002-2005). Diagn. Microbiol. Infect. Dis. 57 (2007) 459-465
15. Robert J., Bismuth R., and Jarlier V. Decreased susceptibility to glycopeptides in methicillin-resistant Staphylococcus aureus: a 20 year study in a large French teaching hospital, 1983-2002. J. Antimicrob. Chemother. 57 (2006) 506-510
16. Sader H.S., Fritsche T.R., and Jones R.N. Daptomycin bactericidal activity and correlation between disk and broth microdilution method results in testing of Staphylococcus aureus strains with decreased susceptibility to vancomycin. Antimicrob. Agents Chemother. 50 (2006) 2330-2336
17. Sader H.S., Streit J.M., Fritsche T.R., and Jones R.N. Antimicrobial susceptibility of gram-positive bacteria isolated from European medical centres: results of the Daptomycin Surveillance Programme (2002-2004). Clin. Microbiol. Infect. 12 (2006) 844-852
18. Sakoulas G., Moise-Broder P.A., Schentag J., Forrest A., Moellering Jr. R.C., and Eliopoulos G.M. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J. Clin. Microbiol. 42 (2004) 2398-2402
19. Sancak B., Ercis S., Menemenlioglu D., Colakoglu S., and Hascelik G. Methicillin-resistant Staphylococcus aureus heterogeneously resistant to vancomycin in a Turkish university hospital. J. Antimicrob. Chemother. 56 (2005) 519-523
20. Soriano A., Marco F., Martinez J.A., Pisos E., Almela M., Dimova V.P., Alamo D., Ortega M., Lopez J., and Mensa J. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin. Infect. Dis. 46 (2008) 193-200
21. Steinkraus G., White R., and Friedrich L. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05. J. Antimicrob. Chemother. 60 (2007) 788-794
22. Trueba F., Garrabe E., Hadef R., Fabre R., Cavallo J.D., Tsvetkova K., and Chesneau O. High prevalence of teicoplanin resistance among Staphylococcus epidermidis strains in a 5-year retrospective study. J. Clin. Microbiol. 44 (2006) 1922-1923